182 related articles for article (PubMed ID: 28784116)
1. Gene expression profiling in patients with polymyalgia rheumatica before and after symptom-abolishing glucocorticoid treatment.
Kreiner FF; Borup R; Nielsen FC; Schjerling P; Galbo H
BMC Musculoskelet Disord; 2017 Aug; 18(1):341. PubMed ID: 28784116
[TBL] [Abstract][Full Text] [Related]
2. Whole-body MRI of patients with polymyalgia rheumatica identifies a distinct subset with complete patient-reported response to glucocorticoids.
Mackie SL; Pease CT; Fukuba E; Harris E; Emery P; Hodgson R; Freeston J; McGonagle D
Ann Rheum Dis; 2015 Dec; 74(12):2188-92. PubMed ID: 26376658
[TBL] [Abstract][Full Text] [Related]
3. Elevated muscle interstitial levels of pain-inducing substances in symptomatic muscles in patients with polymyalgia rheumatica.
Kreiner F; Galbo H
Pain; 2011 May; 152(5):1127-1132. PubMed ID: 21388741
[TBL] [Abstract][Full Text] [Related]
4. Insulin sensitivity and related cytokines, chemokines, and adipokines in polymyalgia rheumatica.
Kreiner F; Galbo H
Scand J Rheumatol; 2010; 39(5):402-8. PubMed ID: 20615159
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica.
Owen CE; McMaster C; Liew DFL; Leung JL; Scott AM; Buchanan RRC
Int J Rheum Dis; 2021 Jan; 24(1):56-62. PubMed ID: 33043616
[TBL] [Abstract][Full Text] [Related]
6. Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6.
Cutolo M; Straub RH; Foppiani L; Prete C; Pulsatelli L; Sulli A; Boiardi L; Macchioni P; Giusti M; Pizzorni C; Seriolo B; Salvarani C
J Rheumatol; 2002 Apr; 29(4):748-56. PubMed ID: 11950017
[TBL] [Abstract][Full Text] [Related]
7. Circadian variations in clinical symptoms and concentrations of inflammatory cytokines, melatonin, and cortisol in polymyalgia rheumatica before and during prednisolone treatment: a controlled, observational, clinical experimental study.
Galbo H; Kall L
Arthritis Res Ther; 2016 Jul; 18(1):174. PubMed ID: 27455959
[TBL] [Abstract][Full Text] [Related]
8. Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica.
Kreiner F; Langberg H; Galbo H
Arthritis Rheum; 2010 Dec; 62(12):3768-75. PubMed ID: 20812339
[TBL] [Abstract][Full Text] [Related]
9. Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica.
Braun N; Fritz P; Rieth A; Schroth W; Kimmel M; Biegger D; Zakim D; Alscher MD
J Rheumatol; 2009 Oct; 36(10):2269-76. PubMed ID: 19684157
[TBL] [Abstract][Full Text] [Related]
10. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.
Salvarani C; Cantini F; Niccoli L; Macchioni P; Consonni D; Bajocchi G; Vinceti M; Catanoso MG; Pulsatelli L; Meliconi R; Boiardi L
Arthritis Rheum; 2005 Feb; 53(1):33-8. PubMed ID: 15696567
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial.
Ma X; Yang F; Wu J; Xu B; Jiang M; Sun Y; Sun C; Yu Y; Xu D; Xiao L; Ren C; Chen C; Ye Z; Liang J; Lin J; Chen W
PLoS Med; 2023 Jun; 20(6):e1004249. PubMed ID: 37384596
[TBL] [Abstract][Full Text] [Related]
12. The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis.
Jakobsson K; Jacobsson L; Mohammad AJ; Nilsson JÅ; Warrington K; Matteson EL; Turesson C
BMC Musculoskelet Disord; 2016 Aug; 17(1):363. PubMed ID: 27558589
[TBL] [Abstract][Full Text] [Related]
13. Polymyalgia rheumatica and colon malignacy: case report.
Kehler T; Curković B
Clin Rheumatol; 2006 Sep; 25(5):764-5. PubMed ID: 16249824
[TBL] [Abstract][Full Text] [Related]
14. The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica.
Schreiber S; Buyse M
Clin Rheumatol; 1995 May; 14(3):315-8. PubMed ID: 7641508
[TBL] [Abstract][Full Text] [Related]
15. Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable.
Devauchelle-Pensec V; Saraux L; Berthelot JM; De Bandt M; Cornec D; Guellec D; Marhadour T; Jousse-Joulin S; Gouillou M; Saraux A
Rheumatology (Oxford); 2018 Apr; 57(4):666-670. PubMed ID: 29346621
[TBL] [Abstract][Full Text] [Related]
16. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica.
Dolan AL; Moniz C; Dasgupta B; Li F; Mackintosh C; Todd P; Corrigall V; Panayi GS
Arthritis Rheum; 1997 Nov; 40(11):2022-9. PubMed ID: 9365092
[TBL] [Abstract][Full Text] [Related]
17. Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.
Martinez-Taboada VM; Blanco R; Fito C; Pacheco MJ; Delgado-Rodriguez M; Rodriguez-Valverde V
Semin Arthritis Rheum; 2001 Feb; 30(4):257-71. PubMed ID: 11182026
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid treatment of polymyalgia rheumatica.
Caporali R; Cimmino MA; Montecucco C; Cutolo M
Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S143-7. PubMed ID: 22018201
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature.
Macchioni P; Boiardi L; Catanoso M; Pulsatelli L; Pipitone N; Meliconi R; Salvarani C
Semin Arthritis Rheum; 2013 Aug; 43(1):113-8. PubMed ID: 23433960
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid effects on adrenal steroids and cytokine responsiveness in polymyalgia rheumatica and elderly onset rheumatoid arthritis.
Sulli A; Montecucco CM; Caporali R; Cavagna L; Montagna P; Capellino S; Fazzuoli L; Seriolo B; Alessandro C; Secchi ME; Cutolo M
Ann N Y Acad Sci; 2006 Jun; 1069():307-14. PubMed ID: 16855158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
